LOXL2 and neoplasm: Interestingly, an opposite function has been proposed for the prototypic member of the family; Lox promoter polymorphisms were associated with OS risk,72 Lox expression was decreased in OS samples and Lox had tumor suppressor activity in OS cell lines.73 Nevertheless, our in vivo experiments using H2-c-fosLTR mice and human and mouse OS xenografts indicate that tumor size was significantly reduced and collagen packing density substantially affected when Loxl2 was inhibited either pharmacologically together with Lox or specifically by shRNA or by blocking antibodies.